This week, the US Food and Drug Administration
approved Aduhelm (aducanumab) to treat patients with Alzheimer's disease using an accelerated approval pathway.
The drug was approved on June 7, 2021, and the decision was quick to spark controversy. At least two members of a panel of outside advisors to the FDA from Mayo Clinic and Washington University
resigned in protest over the drug's approval.
Clinical trials for the drug, which is manufactured by Biogen, showed a reduction in amyloid beta plaques. According to the FDA, that is "a hallmark finding in the brain of patients with Alzheimer's" and "is expected to lead to a reduction in the clinical decline of this...form of dementia."
But there
remain concerns about the drug's side effects in addition to its price tag.
Health Affairs' Senior Editor Leslie Erdelack joins Deputy Editor for Special Content Rob Lott on this episode of
Health Affairs This Week to discuss the approval and review outstanding questions, drug pricing, and whether pharmaceutical companies might look to old data for new drug approvals.
Related Links:From our advertiser: Our UnitedHealthcare Community & State newsletter is your go-to source for the latest Medicaid news and UnitedHealthcare programs serving Medicaid beneficiaries. Subscribe now by visiting our website at
UHCCS.com/Newsletter. Stay in the know by gaining access to our latest blogs, educational videos and upcoming events.